Orally Administered SYN-020 Observed to be Well Tolerated in Healthy Volunteers; A Second Phase 1 Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 ROCKVILLE, Md., June 29, 2021 ...

Synthetic Biologics is teaming up with gut microbiome specialists Enterome Bioscience to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora of ...

ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of ...

There is now growing renewed interest in gene therapy as several recent successful clinical trials have now overcome prior technical challenges in the space. Gene therapy involves treating disease by ...

Synthetic Biologics, a biologics and drug development company, has announced its second quarter financial results. Here are three things to know about the company and its financial performance. 1. The ...

Synthetic Biologics has formed a clinical advisory board to support development of SYN-004, its lead anti-infective product candidate for the prevention of the effects of Clostridium difficile. The ...

Synthetic Biologics, a clinical stage company developing therapeutics to protect the gut microbiome, named Isaac J. Bright, MD, vice president, corporate development. 1. Dr. Bright will be responsible ...

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (SYN) (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas ...

-The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) - ...

Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome ...

ROCKVILLE, Md. (AP) _ Synthetic Biologics Inc. (SYN) on Wednesday reported a loss of $10.9 million in its third quarter. The Rockville, Maryland-based company said it had a loss of 14 cents per share.

Acquisition of Rodon Biologics brings operational R&D capability, skilled talent, know-how, drives capital-efficiency, synthetic biology synergy in biopharma. DUBLIN ...